Intensive vs More Intensive Lipid-Lowering Therapy in Statin-Naive Patients jamanetwork.com/journals/jam...
Can coronary atherosclerosis actually regress?
FLOWPROMOTE trial analysis, published in JAMA Cardiology, shows remarkable coronary plaque regression with intensive LDL-C lowering.
Can coronary atherosclerosis actually regress?
FLOWPROMOTE trial analysis, published in JAMA Cardiology, shows remarkable coronary plaque regression with intensive LDL-C lowering.
Intensive vs More Intensive Lipid-Lowering Therapy in Statin-Naive Patients
This secondary analysis of the FLOWPROMOTE randomized clinical trial investigates if more intensive lipid-lowering therapy leads to greater regression of coronary atherosclerotic plaque across the ent...
jamanetwork.com
November 2, 2026 at 4:00 AM
Intensive vs More Intensive Lipid-Lowering Therapy in Statin-Naive Patients jamanetwork.com/journals/jam...
Can coronary atherosclerosis actually regress?
FLOWPROMOTE trial analysis, published in JAMA Cardiology, shows remarkable coronary plaque regression with intensive LDL-C lowering.
Can coronary atherosclerosis actually regress?
FLOWPROMOTE trial analysis, published in JAMA Cardiology, shows remarkable coronary plaque regression with intensive LDL-C lowering.
#Cardiovascular Outcomes of #Triglyceride-Targeting #Lipid-Lowering Therapies in Patients with #CKD
#VisualAbstract by Vamsidhar Veeranki
https://www.kireports.org/article/S2468-0249(26)03348-6/fulltext
#VisualAbstract by Vamsidhar Veeranki
https://www.kireports.org/article/S2468-0249(26)03348-6/fulltext
October 30, 2026 at 1:00 PM
#Cardiovascular Outcomes of #Triglyceride-Targeting #Lipid-Lowering Therapies in Patients with #CKD
#VisualAbstract by Vamsidhar Veeranki
https://www.kireports.org/article/S2468-0249(26)03348-6/fulltext
#VisualAbstract by Vamsidhar Veeranki
https://www.kireports.org/article/S2468-0249(26)03348-6/fulltext
Published in @eclinicalmed.bsky.social
Comparative effectiveness of #lipid-lowering therapies for primary #cardiovascular prevention: a network meta-analysis of randomised controlled trials www.thelancet.com/journals/ecl...
#ASCVD
#OpenAccess
#MedSky #EndoSky #CardioSky
Comparative effectiveness of #lipid-lowering therapies for primary #cardiovascular prevention: a network meta-analysis of randomised controlled trials www.thelancet.com/journals/ecl...
#ASCVD
#OpenAccess
#MedSky #EndoSky #CardioSky
Comparative effectiveness of lipid-lowering therapies for primary cardiovascular prevention: a network meta-analysis of randomised controlled trials
Benefit in primary prevention tracked statin intensity rather than drug class. Evolocumab
added to a statin conferred further benefit over that statin, whereas EPA and fibrates
did not, and bempedoic ...
www.thelancet.com
October 29, 2026 at 8:32 AM
Published in @eclinicalmed.bsky.social
Comparative effectiveness of #lipid-lowering therapies for primary #cardiovascular prevention: a network meta-analysis of randomised controlled trials www.thelancet.com/journals/ecl...
#ASCVD
#OpenAccess
#MedSky #EndoSky #CardioSky
Comparative effectiveness of #lipid-lowering therapies for primary #cardiovascular prevention: a network meta-analysis of randomised controlled trials www.thelancet.com/journals/ecl...
#ASCVD
#OpenAccess
#MedSky #EndoSky #CardioSky
#Cholesterol-lowering medicine has changed almost beyond recognition over the past 25 years—from early #statin trials to today's longer-acting, less frequently dosed therapies, some of which may eventually require only one or two doses a year youtube.com/watch?v=atCH...
#LDL
#EndoSky #CardioSky
#LDL
#EndoSky #CardioSky
25 Years of Lipid Medicine
YouTube video by The Lancet
youtube.com
October 29, 2026 at 3:42 PM
#Cholesterol-lowering medicine has changed almost beyond recognition over the past 25 years—from early #statin trials to today's longer-acting, less frequently dosed therapies, some of which may eventually require only one or two doses a year youtube.com/watch?v=atCH...
#LDL
#EndoSky #CardioSky
#LDL
#EndoSky #CardioSky
More intensive vs intensive statin therapy in statin-naive stable CAD (FLOWPROMOTE secondary analysis, n=104, 18 mo)
Rosuvastatin 40 + ezetimibe vs atorvastatin 40:
LDL-C: 42.5 vs 69.5 mg/dL
Total plaque volume: −69.8 vs −39.0 mm³ (difference −30.9 mm³, P=.02)
JAMA Cardiol
Rosuvastatin 40 + ezetimibe vs atorvastatin 40:
LDL-C: 42.5 vs 69.5 mg/dL
Total plaque volume: −69.8 vs −39.0 mm³ (difference −30.9 mm³, P=.02)
JAMA Cardiol
Intensive vs More Intensive Lipid-Lowering Therapy and Plaque… · CurrentCardio
Randomized controlled trial · 104 patients · JAMA Cardiol, 2026. This secondary analysis of the FLOWPROMOTE randomized clinical trial demonstrated that in statin-naive patients with CAD, more intensiv...
currentcardio.com
October 31, 2026 at 8:42 AM
More intensive vs intensive statin therapy in statin-naive stable CAD (FLOWPROMOTE secondary analysis, n=104, 18 mo)
Rosuvastatin 40 + ezetimibe vs atorvastatin 40:
LDL-C: 42.5 vs 69.5 mg/dL
Total plaque volume: −69.8 vs −39.0 mm³ (difference −30.9 mm³, P=.02)
JAMA Cardiol
Rosuvastatin 40 + ezetimibe vs atorvastatin 40:
LDL-C: 42.5 vs 69.5 mg/dL
Total plaque volume: −69.8 vs −39.0 mm³ (difference −30.9 mm³, P=.02)
JAMA Cardiol
Lena E. Tran, MD, and Joshua A. Beckman, MD, examine the shifting paradigm in medical management of PAD by reviewing lipid-lowering, antithrombotic, and cardiometabolic therapies, as well as the growing emphasis on comprehensive, guideline-directed care. https://ow.ly/LXKB50ZZRx5
October 22, 2026 at 7:10 PM
Lena E. Tran, MD, and Joshua A. Beckman, MD, examine the shifting paradigm in medical management of PAD by reviewing lipid-lowering, antithrombotic, and cardiometabolic therapies, as well as the growing emphasis on comprehensive, guideline-directed care. https://ow.ly/LXKB50ZZRx5
Patients with high-risk #diabetes or #atherosclerosis but no prior #stroke or myocardial infarction experience improved overall survival when evolocumab is added to background lipid-lowering therapy.
https://bit.ly/4ysg2G5
https://bit.ly/4ysg2G5
Evolocumab Lowers Mortality in High-Risk Patients Without Prior Stroke or MI
Adding evolocumab to lipid-lowering therapy reduces all-cause mortality in high-risk patients without a history of myocardial infarction or stroke.
www.thecardiologyadvisor.com
October 20, 2026 at 6:20 PM
Patients with high-risk #diabetes or #atherosclerosis but no prior #stroke or myocardial infarction experience improved overall survival when evolocumab is added to background lipid-lowering therapy.
https://bit.ly/4ysg2G5
https://bit.ly/4ysg2G5
New publication: Early lipid-lowering strategies after acute coronary syndrome: strike strong or start smart?. Congratulations to the authors!
pubmed.ncbi.nlm.nih.gov/42667313/
#CVRCBern
pubmed.ncbi.nlm.nih.gov/42667313/
#CVRCBern
October 20, 2026 at 10:02 AM
New publication: Early lipid-lowering strategies after acute coronary syndrome: strike strong or start smart?. Congratulations to the authors!
pubmed.ncbi.nlm.nih.gov/42667313/
#CVRCBern
pubmed.ncbi.nlm.nih.gov/42667313/
#CVRCBern
ICYMI - 25 Years of Lipid Medicine youtube.com/watch?v=atCH...
Cholesterol-lowering medicine has changed almost beyond recognition over the past 25 years—from early statin trials to today's longer-acting, less frequently dosed therapies.
#statins #LDL #cholesterol #PCSK9 inhibitors
#CardioSky
Cholesterol-lowering medicine has changed almost beyond recognition over the past 25 years—from early statin trials to today's longer-acting, less frequently dosed therapies.
#statins #LDL #cholesterol #PCSK9 inhibitors
#CardioSky
25 Years of Lipid Medicine
YouTube video by The Lancet
youtube.com
October 16, 2026 at 12:17 PM
ICYMI - 25 Years of Lipid Medicine youtube.com/watch?v=atCH...
Cholesterol-lowering medicine has changed almost beyond recognition over the past 25 years—from early statin trials to today's longer-acting, less frequently dosed therapies.
#statins #LDL #cholesterol #PCSK9 inhibitors
#CardioSky
Cholesterol-lowering medicine has changed almost beyond recognition over the past 25 years—from early statin trials to today's longer-acting, less frequently dosed therapies.
#statins #LDL #cholesterol #PCSK9 inhibitors
#CardioSky
Cardiometabolic Disease Market: Advanced Lipid-Lowering Treatments and Cholesterol Control
Contact Us
U.S.: +1 646 905 0080
India: +91 8087085354
U.K.: +44 203 695 0070
Email:https://straitsresearch.com/report/cardiometabolic-disease-market
Contact Us
U.S.: +1 646 905 0080
India: +91 8087085354
U.K.: +44 203 695 0070
Email:https://straitsresearch.com/report/cardiometabolic-disease-market
October 15, 2026 at 11:56 AM
Cardiometabolic Disease Market: Advanced Lipid-Lowering Treatments and Cholesterol Control
Contact Us
U.S.: +1 646 905 0080
India: +91 8087085354
U.K.: +44 203 695 0070
Email:https://straitsresearch.com/report/cardiometabolic-disease-market
Contact Us
U.S.: +1 646 905 0080
India: +91 8087085354
U.K.: +44 203 695 0070
Email:https://straitsresearch.com/report/cardiometabolic-disease-market
Editas clears Australian regulatory approval to start Phase 1/2 trial of EDIT-401, an in vivo gene editor for hyperlipidaemia. First clinical data from the Strive study could reshape lipid-lowering therapeutics.
Editas Medicine clears first hurdle for EDIT-401 hyperlipidaemia trial
Editas has received ethics and regulatory approval in Australia to begin its Phase 1/2 Strive trial of in vivo gene editor EDIT-401 in
biotech.disruptsmedia.com
October 13, 2026 at 6:45 AM
Editas clears Australian regulatory approval to start Phase 1/2 trial of EDIT-401, an in vivo gene editor for hyperlipidaemia. First clinical data from the Strive study could reshape lipid-lowering therapeutics.
#Cholesterol-lowering medicine has changed almost beyond recognition over the past 25 years—from early #statin trials to today's longer-acting, less frequently dosed therapies, some of which may eventually require only one or two doses a year youtube.com/watch?v=atCH...
#LDL #CVD
#MedSky #CardioSky
#LDL #CVD
#MedSky #CardioSky
25 Years of Lipid Medicine
YouTube video by The Lancet
youtube.com
October 11, 2026 at 10:21 AM
#Cholesterol-lowering medicine has changed almost beyond recognition over the past 25 years—from early #statin trials to today's longer-acting, less frequently dosed therapies, some of which may eventually require only one or two doses a year youtube.com/watch?v=atCH...
#LDL #CVD
#MedSky #CardioSky
#LDL #CVD
#MedSky #CardioSky
Read more about the evolution of novel pharmacological approaches for lipid lowering during the first quarter of the 21st century
thelancet.com/journals/lan...
#LDL #cholesterol #cardiovascular #disease #prevention
#MedSky #EndoSky #CardioSky
thelancet.com/journals/lan...
#LDL #cholesterol #cardiovascular #disease #prevention
#MedSky #EndoSky #CardioSky
October 11, 2026 at 10:21 AM
Read more about the evolution of novel pharmacological approaches for lipid lowering during the first quarter of the 21st century
thelancet.com/journals/lan...
#LDL #cholesterol #cardiovascular #disease #prevention
#MedSky #EndoSky #CardioSky
thelancet.com/journals/lan...
#LDL #cholesterol #cardiovascular #disease #prevention
#MedSky #EndoSky #CardioSky
Inflammation and endothelial dysfunction in the trigeminovascular system are the suggested underlying mechanisms. Statins, beyond their lipid-lowering effects, exhibit pleiotropic properties including anti-inflammatory, antioxidative, and endothelial-modulating effects, which may (🧵 2/9)
October 10, 2026 at 8:32 AM
Inflammation and endothelial dysfunction in the trigeminovascular system are the suggested underlying mechanisms. Statins, beyond their lipid-lowering effects, exhibit pleiotropic properties including anti-inflammatory, antioxidative, and endothelial-modulating effects, which may (🧵 2/9)
❤️🩺 Toxic lipids may contribute to heart and kidney damage in Cardiovascular-Kidney-Metabolic Syndrome (CKMS). This review highlights their role in disease progression and the potential of targeted lipid-lowering therapies. 🔬 #CKMS
mdpi.com/2227-9059/12...
mdpi.com/2227-9059/12...
October 8, 2026 at 12:12 AM
❤️🩺 Toxic lipids may contribute to heart and kidney damage in Cardiovascular-Kidney-Metabolic Syndrome (CKMS). This review highlights their role in disease progression and the potential of targeted lipid-lowering therapies. 🔬 #CKMS
mdpi.com/2227-9059/12...
mdpi.com/2227-9059/12...
Colestipol Market Opens New Growth Pathways in Cardiovascular Care Through 2034
The global Colestipol Market was valued at US$ 158.52 million in 2025 and is expected to reach US$ 202.46 million by 2034, registering a CAGR of 2.76% during 2026–2034. Colestipol is a bile acid sequestrant used to…
The global Colestipol Market was valued at US$ 158.52 million in 2025 and is expected to reach US$ 202.46 million by 2034, registering a CAGR of 2.76% during 2026–2034. Colestipol is a bile acid sequestrant used to…
Colestipol Market Opens New Growth Pathways in Cardiovascular Care Through 2034
The global Colestipol Market was valued at US$ 158.52 million in 2025 and is expected to reach US$ 202.46 million by 2034, registering a CAGR of 2.76% during 2026–2034. Colestipol is a bile acid sequestrant used to help reduce elevated cholesterol levels by binding bile acids in the digestive tract and promoting their elimination. Its established role in lipid management, continued demand for cholesterol-lowering therapies, and availability through pharmaceutical channels are supporting the market.
www.news24.ph
October 8, 2026 at 6:37 AM
Colestipol Market Opens New Growth Pathways in Cardiovascular Care Through 2034
The global Colestipol Market was valued at US$ 158.52 million in 2025 and is expected to reach US$ 202.46 million by 2034, registering a CAGR of 2.76% during 2026–2034. Colestipol is a bile acid sequestrant used to…
The global Colestipol Market was valued at US$ 158.52 million in 2025 and is expected to reach US$ 202.46 million by 2034, registering a CAGR of 2.76% during 2026–2034. Colestipol is a bile acid sequestrant used to…
"the research found that post-menopausal women [with Type 1 diabetes] had a higher risk of retinopathy, cardiovascular disease, neuropathy, falls, and moderate-to-severe depressive symptoms.
They were also less likely to have been prescribed antihypertensive and lipid-lowering medications."
They were also less likely to have been prescribed antihypertensive and lipid-lowering medications."
Health of women with diabetes may deteriorate after menopause: study
Health of women with diabetes may deteriorate after menopause: study
Women with Type 1 diabetes appear to be at greater risk of physical and psychosocial health problems after menopause and require an updated treatment plan, according to a new study.
www.ctvnews.ca
October 1, 2026 at 8:43 PM
"the research found that post-menopausal women [with Type 1 diabetes] had a higher risk of retinopathy, cardiovascular disease, neuropathy, falls, and moderate-to-severe depressive symptoms.
They were also less likely to have been prescribed antihypertensive and lipid-lowering medications."
They were also less likely to have been prescribed antihypertensive and lipid-lowering medications."
Dr. Ben Lidgard discusses "Lipid Lowering in CKD: The Nephrologist's Role" in his Grand Rounds presentation @uwnephrology.bsky.social @uwdeptmedicine.bsky.social
#nephsky #kidney #CKD #Lipid #cholesterol
youtu.be/Qq5BXEbhF2k?...
#nephsky #kidney #CKD #Lipid #cholesterol
youtu.be/Qq5BXEbhF2k?...
Benjamin Lidgard, MD - Lipid Lowering In CKD: The Nephrologist’s Role
YouTube video by University of Washington Division of Nephrology
youtu.be
September 30, 2026 at 6:02 PM
Dr. Ben Lidgard discusses "Lipid Lowering in CKD: The Nephrologist's Role" in his Grand Rounds presentation @uwnephrology.bsky.social @uwdeptmedicine.bsky.social
#nephsky #kidney #CKD #Lipid #cholesterol
youtu.be/Qq5BXEbhF2k?...
#nephsky #kidney #CKD #Lipid #cholesterol
youtu.be/Qq5BXEbhF2k?...
What’s the future of #CAD #pharmacotherapy?
This review details novel lipid‑lowering agents, anti‑inflammatory therapies, metabolic modulators, & precision medicine approaches, charting path toward safer, more effective CAD treatments #Cardiology #CVIA
#OpenAccess: cvia-journal.org/advances-in-...
This review details novel lipid‑lowering agents, anti‑inflammatory therapies, metabolic modulators, & precision medicine approaches, charting path toward safer, more effective CAD treatments #Cardiology #CVIA
#OpenAccess: cvia-journal.org/advances-in-...
September 28, 2026 at 7:48 AM
What’s the future of #CAD #pharmacotherapy?
This review details novel lipid‑lowering agents, anti‑inflammatory therapies, metabolic modulators, & precision medicine approaches, charting path toward safer, more effective CAD treatments #Cardiology #CVIA
#OpenAccess: cvia-journal.org/advances-in-...
This review details novel lipid‑lowering agents, anti‑inflammatory therapies, metabolic modulators, & precision medicine approaches, charting path toward safer, more effective CAD treatments #Cardiology #CVIA
#OpenAccess: cvia-journal.org/advances-in-...
One CRISPR treatment cut “bad” cholesterol in half for a full year
One CRISPR treatment cut “bad” cholesterol in half for a full year
A single dose of an experimental CRISPR therapy cut LDL cholesterol and triglycerides by about half in patients with difficult-to-treat lipid disorders. The reductions were still present one year later, with the highest dose lowering LDL by 52.5% and triglycerides by 47.8%.
www.sciencedaily.com
September 28, 2026 at 3:12 AM
One CRISPR treatment cut “bad” cholesterol in half for a full year
Ophthopedia Update: Potential protective associations of antidiabetic and lipid-lowering therapies with retinal vein occlusion risk: a systematic review and meta-analysis: Eye, Published online: 24 September 2026; doi:10.1038/s41433-026-04904-4Potential… #Ophthalmology #Eye #Ophthotwitter
Potential protective associations of antidiabetic and lipid-lowering therapies with retinal vein occlusion risk: a systematic review and meta-analysis
Eye, Published online: 24 September 2026; doi:10.1038/s41433-026-04904-4Potential protective associations of antidiabetic and lipid-lowering therapies with retinal vein occlusion risk: a systematic review and meta-analysis
dlvr.it
September 25, 2026 at 2:07 AM
Ophthopedia Update: Potential protective associations of antidiabetic and lipid-lowering therapies with retinal vein occlusion risk: a systematic review and meta-analysis: Eye, Published online: 24 September 2026; doi:10.1038/s41433-026-04904-4Potential… #Ophthalmology #Eye #Ophthotwitter
Lipid lowering effects of Fucus vesiculosus and Phytolacca berry extracts: An alternative approach of treating hypertriglyceridemia https://www.biorxiv.org/content/10.64898/2026.09.18.752646v1
September 25, 2026 at 1:00 AM
Lipid lowering effects of Fucus vesiculosus and Phytolacca berry extracts: An alternative approach of treating hypertriglyceridemia https://www.biorxiv.org/content/10.64898/2026.09.18.752646v1
Lipid lowering effects of Fucus vesiculosus and Phytolacca berry extracts: An alternative approach of treating hypertriglyceridemia https://www.biorxiv.org/content/10.64898/2026.09.18.752646v1
September 25, 2026 at 1:00 AM
Lipid lowering effects of Fucus vesiculosus and Phytolacca berry extracts: An alternative approach of treating hypertriglyceridemia https://www.biorxiv.org/content/10.64898/2026.09.18.752646v1
Researchers gave mice pemafibrate, a lipid-lowering drug, from 7 days before a temporary brain artery blockage through 2 days after. At the highest dose, average stroke-damaged tissue volume was about half that seen without the drug.
September 23, 2026 at 12:15 PM
Researchers gave mice pemafibrate, a lipid-lowering drug, from 7 days before a temporary brain artery blockage through 2 days after. At the highest dose, average stroke-damaged tissue volume was about half that seen without the drug.
#Cholesterol-lowering medicine has changed almost beyond recognition over the past 25 years — from early #statin trials to today's longer-acting, less frequently dosed therapies, some of which may eventually require only one or two doses a year www.youtube.com/watch?v=atCH...
#LDL #ASCVD
#EndoSky
#LDL #ASCVD
#EndoSky
25 Years of Lipid Medicine
YouTube video by The Lancet
www.youtube.com
September 23, 2026 at 8:35 AM
#Cholesterol-lowering medicine has changed almost beyond recognition over the past 25 years — from early #statin trials to today's longer-acting, less frequently dosed therapies, some of which may eventually require only one or two doses a year www.youtube.com/watch?v=atCH...
#LDL #ASCVD
#EndoSky
#LDL #ASCVD
#EndoSky